The balance sheet has strengthened significantly, with equity rising from $63.0M to $507.3M and D/E improving from 3.40 to 0.51, but retained earnings remain negative at -$173.5M, indicating reliance on external capital.
Nutex Health, Inc. (NUTX) balance sheet — 13-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'11 | Dec'10 |
|---|
| Total Current Assets | 585.65M | 538.81M | 292.48M | 90.85M | 97.97M | 154.02M | 135.51M | 45.74M | 305.42K | 55.08K | 507.93K | 7.63M | 1.76M | 2.22M |
| Cash & Short-Term Investments | 205.21M | 185.57M | 43.58M | 22M | 34.26M | 36.12M | 25.51M | 8M | 119.27K | 9.45K | 10.52K | 122.29K | 224.8K | 465.55K |
| Cash Only | 205.21M | 185.57M | 43.58M | 22M | 34.26M | 36.12M | 25.51M | 8M | 119.27K | 9.45K | 10.52K | 122.29K | 224.8K | 465.55K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 351.68M | 325.42M | 236.05M | 62.78M | 58.32M | 114.76M | 108.14M | 36.14M | 186.15K | 6.25K | 15K | 0 | 720.87K | 613.65K |
| Days Sales Outstanding | 151.31 | 135.71 | 179.52 | 92.52 | 97.06 | 126.34 | 144.04 | 135.91 | 743.6 | 42.55 | - | - | 103.24 | 176.87 |
| Inventory | 4.21M | 2.87M | 2.85M | 3.39M | 3.53M | 2.81M | 1.73M | 899.91K | 27.07K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 3.3 | 2.43 | 3.67 | 5.81 | 6.33 | 6.75 | 5.41 | - | 158.62 | - | - | - | - | - |
| Other Current Assets | 24.56M | 24.95M | 10M | 2.68M | 1.87M | 323.28K | 0 | 0 | -27.07K | 39.38K | 482.41K | 7.27M | 754.77K | 812.73K |
| Total Non-Current Assets | 378.98M | 379.71M | 362.84M | 307.4M | 333.78M | 240.63M | 173.05M | 133.48M | 144.01K | 3.27M | 2.9K | 3.38K | 313.77K | 116.11K |
| Property, Plant & Equipment | 340.92M | 343.9M | 324.69M | 269.39M | 295.15M | 238.36M | 170.81M | 131.28M | 7.61K | 3.85K | 1.18K | 1.66K | 18.56K | 5.09K |
| Fixed Asset Turnover | 2.49x | 2.55x | 1.48x | 0.92x | 0.74x | 1.39x | 1.60x | 0.74x | 12.00x | 13.95x | - | - | 137.30x | 248.94x |
| Goodwill | 13.92M | 13.92M | 13.92M | 17.07M | 17.01M | 1.14M | 1.14M | 3.47M | 0 | 0 | 0 | 0 | 111.03K | 111.03K |
| Intangible Assets | 20.58M | 21.23M | 15.53M | 20.51M | 21.19M | 682.65K | 0 | 1.54M | 2.57M | 3.27M | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100K | 116.96K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 3.56M | 662K | 711.35K | 431.13K | 423.43K | 456.08K | 1.1M | -2.81M | 19.43K | 1.95K | 1.72K | 1.72K | 0 | 0 |
| Total Assets | 964.63M | 918.52M | 655.32M | 398.25M | 431.75M | 394.65M | 308.55M | 179.22M | 449.43K | 3.33M | 510.83K | 7.64M | 2.07M | 2.33M |
| Asset Turnover | 0.89x | 0.95x | 0.73x | 0.62x | 0.51x | 0.84x | 0.89x | 0.54x | 0.20x | 0.02x | - | - | 1.23x | 0.54x |
| Asset Growth % | 200.47% | 40.16% | 64.55% | -7.76% | 9.4% | 27.9% | 72.16% | 39778.36% | -86.5% | 551.63% | -93.31% | 268.48% | -11.2% | - |
| Total Current Liabilities | 117.22M | 157.91M | 140.87M | 58.31M | 54.86M | 37.69M | 31.45M | 72.13M | 1.04M | 959.78K | 6.38M | 6.08M | 288.58K | 351.62K |
| Accounts Payable | 4.28M | 48.97M | 13.96M | 25.28M | 23.93M | 17.65M | 8.63M | 1.75M | 567.01K | 348.35K | 356K | 168.97K | 263.19K | 326.23K |
| Days Payables Outstanding | 33.87 | 41.47 | 17.96 | 43.35 | 42.84 | 42.32 | 27.06 | - | 3.32K | 225.3 | 274.72K | 93.16K | 62.81 | 152.04 |
| Short-Term Debt | 18M | 14.08M | 17.95M | 14.18M | 15.17M | 10.23M | 18.65M | 13.35M | 477.06K | 386.19K | 50K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 173.92K | 38.65K | 165.56K | 9.19K | 9.1K | 0 | 811.23K | 0 | 0 |
| Other Current Liabilities | 99.22M | 8.26M | 0 | 0 | 5.61M | 3.6M | -38.65K | 3.37M | 332.19K | 216.14K | 5.97M | 5.1M | 25.39K | 25.39K |
| Current Ratio | 5.00x | 3.41x | 2.08x | 1.56x | 1.79x | 4.09x | 4.31x | 0.63x | 0.29x | 0.06x | 0.08x | 1.26x | 6.10x | 6.31x |
| Quick Ratio | 4.96x | 3.39x | 2.06x | 1.50x | 1.72x | 4.01x | 4.25x | 0.62x | 0.27x | 0.06x | 0.08x | 1.26x | 6.10x | 6.31x |
| Cash Conversion Cycle | 120.74 | 96.66 | 165.22 | 54.99 | 60.55 | 90.77 | 122.39 | - | -2.42K | - | - | - | - | - |
| Total Non-Current Liabilities | 340.1M | 337.18M | 312.56M | 260.83M | 256.56M | 165.38M | 129.73M | 56.26M | 902.72K | 0 | 0 | 0 | 181.69K | 0 |
| Long-Term Debt | 298.13M | 29.17M | 22.47M | 26.31M | 23.05M | 78.82M | 81.9M | 40.88M | 902.72K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 897.83M | 298.91M | 290.1M | 229.37M | 223.06M | 86.56M | 47.83M | 15.38M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 43.06M | 9.09M | 0 | 5.15M | 10.45M | 1.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 31.11M | 0 | 0 | 0 | 0 | -1.75M | 0 | 0 | 0 | 0 | 0 | 0 | 181.69K | 0 |
| Total Liabilities | 457.32M | 495.09M | 453.43M | 319.14M | 311.42M | 203.07M | 161.19M | 128.39M | 1.95M | 959.78K | 6.38M | 6.08M | 470.27K | 351.62K |
| Total Debt | 316.13M | 351.39M | 340.3M | 275.76M | 267.2M | 178.55M | 150.12M | 119.94M | 1.38M | 386.19K | 50K | 0 | 0 | 0 |
| Net Debt | 110.92M | 165.82M | 296.72M | 253.75M | 232.95M | 142.43M | 124.61M | 111.94M | 1.26M | 376.74K | 39.48K | -122.29K | -224.8K | -465.55K |
| Debt / Equity | 0.51x | 0.83x | 1.69x | 3.49x | 2.22x | 0.93x | 1.02x | 2.36x | - | 0.16x | - | - | - | - |
| Debt / EBITDA | 0.82x | 1.19x | 2.27x | - | - | 1.00x | 0.94x | 3.23x | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.29x | 0.56x | 1.98x | - | - | 0.80x | 0.78x | 3.01x | - | - | - | - | - | - |
| Interest Coverage | 12.21x | 12.01x | 6.51x | -1.97x | -32.60x | 28.35x | 23.66x | 10.09x | -1.31x | -15.35x | -173.90x | -169.42x | - | - |
| Total Equity | 620.31M | 423.44M | 201.89M | 79.11M | 120.33M | 191.58M | 147.37M | 50.84M | -1.5M | 2.37M | -5.87M | 1.56M | 1.6M | 1.99M |
| Equity Growth % | 703.75% | 109.73% | 155.22% | -34.26% | -37.19% | 30% | 189.89% | 3495.03% | -163.21% | 140.36% | -475.93% | -2.58% | -19.27% | - |
| Book Value per Share | 86.42 | 62.67 | 39.59 | 17.94 | 28.43 | 48.48 | 34.34 | 12.28 | -0.21 | 0.57 | -2.84 | 0.76 | 1.34 | 1.66 |
| Total Shareholders' Equity | 507.31M | 329.45M | 146.34M | 61.45M | 95.86M | 114.65M | 85.81M | 28.31M | -1.5M | 2.37M | -5.87M | 1.56M | 1.6M | 1.99M |
| Common Stock | 7K | 7K | 5.51K | 676.68K | 650.22K | 592.79K | 5.28K | 4.65K | 1.77K | 126.2K | 39.71K | 39.68K | 0 | 0 |
| Retained Earnings | -173.54M | -286.19M | -356.89M | -409.07M | -363.29M | 102.32M | -18.22M | -12.57M | -5.45M | -9.65M | -10.23M | -2.8M | -824.45K | -441.06K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1M | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 113M | 93.99M | 55.55M | 17.65M | 24.46M | 76.93M | 61.56M | 22.53M | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying NUTX stock.
As of 2025, Nutex Health, Inc. (NUTX) had total assets of $918.5M including $538.8M in current assets.
Nutex Health, Inc. (NUTX) carries total debt of $351.4M, offset by $185.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Nutex Health, Inc. (NUTX) has total shareholders' equity (book value) of $329.4M ($62.67 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Nutex Health, Inc. (NUTX) reported a current ratio of 3.41x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Negative SBC and revenue volatility
Metrics are mathematically derived from official filings.
Balance Sheet Strengthens Rapidly
Nutex Health's equity surged from $63.0M in 2024Q1 to $507.3M in 2026Q2, while total debt fell from $272.4M to $316.1M, per recent SEC filings, indicating a marked deleveraging trend.
The equity expansion is driven by a combination of retained earnings improvement (from -$409.4M to -$173.5M) and likely capital raises, as total assets grew 138% over the period. This suggests the company is transitioning from a highly leveraged, loss-making entity to a more solvent one, though the pace of asset growth warrants scrutiny for acquisition-driven expansion.
Leverage Declines as Debt Stabilizes
D/E ratio improved from 3.40 in 2024Q1 to 0.51 in 2026Q2, with total debt peaking at $389.0M in 2025Q3 before declining to $316.1M, as reported in financial statements, signaling reduced financial risk.
The absolute debt level remains substantial at $316.1M, but the equity base has grown faster, lowering leverage. The reduction in debt from the 2025Q3 peak suggests either debt repayment or conversion, which may indicate improved cash generation or refinancing. Investors should monitor the composition of debt, as the data does not distinguish between short-term and long-term maturities, which could pose refinancing risk if credit conditions tighten.
Asset Mix Shifts Toward Cash and PPE
Cash and PPE grew to $205.2M and $340.9M respectively by 2026Q2, while goodwill remained flat at $13.9M, based on balance sheet data, indicating a tangible asset-heavy expansion.
The increase in PPE from $266.1M to $340.9M suggests significant investment in physical facilities, consistent with a care facilities operator. Goodwill is minimal relative to total assets, reducing impairment risk. The rising cash balance provides a buffer, but the asset growth may be tied to acquisitions, as total assets jumped from $404.3M to $964.6M, which could introduce integration risks.
Equity Quality Improves but Retained Deficit Persists
Retained earnings improved from -$409.4M to -$173.5M over ten quarters, yet remain negative, while equity reached $507.3M, per reported figures, suggesting reliance on external capital rather than organic profitability.
The narrowing deficit indicates improving profitability, but the negative retained earnings imply that the company has not yet generated cumulative profits. The equity growth likely stems from capital raises, as evidenced by the cash balance increase. Stock-based compensation has been negative in some quarters, which may distort equity quality; investors should assess the sustainability of this improvement.
Liquidity Buffer Strengthens Significantly
Current ratio improved from 1.68 in 2024Q1 to 5.00 in 2026Q2, with cash rising from $30.0M to $205.2M, as per balance sheet data, providing a robust cushion against short-term obligations.
The current ratio of 5.00 indicates ample liquidity, far exceeding the peer average of around 1.80. Cash alone covers a substantial portion of total debt, suggesting low near-term solvency risk. However, the high cash balance may be inefficient if not deployed for growth, and the company's operating cash flow volatility could still pose challenges in covering debt service if cash is used for acquisitions or dividends.
Negative SBC Distorts Equity and Cash Flow
Stock-based compensation was negative in several quarters, including -$78.7M in 2025Q2, which may inflate reported operating cash flow and understate equity dilution, based on cash flow statement data, warranting closer scrutiny.
The negative SBC is unusual and could indicate reversals of prior accruals or accounting adjustments, potentially masking true employee compensation costs. This distortion affects both equity quality and cash flow metrics, as operating cash flow may be overstated. Investors should adjust for these non-cash items to assess the company's true earnings power and cash generation sustainability.